Awards as PI
| Funding | ||
|---|---|---|
| Disease Team Therapy Planning I | Stem Cells Secreting GDNF for the Treatment of ALS | $89,834 |
| iPSC Consortia Award | The HD iPSC Consortium: Repeat Length Dependent Phenotypes for Assay Development | $300,000 |
| Tools and Technologies II | Use of iPS cells (iPSCs) to develop novels tools for the treatment of spinal muscular atrophy. | $1,933,022 |
| Disease Team Therapy Development - Research | Progenitor Cells Secreting GDNF for the Treatment of ALS | $17,842,617 |
Total: $20,165,473.00 |
